Low Testosterone: Do You Need TRT or Is There Something to Try First

Testosterone is made through a chain, and the chain has two distinct places where it can break, and those two places require completely different fixes.

The chain works like this. Your brain sends a signal to your pituitary gland, which is a small structure at the base of your skull, and the pituitary releases two hormones called LH and FSH, which stands for luteinizing hormone and follicle-stimulating hormone. Those hormones travel through your bloodstream to your testicles and tell them to produce testosterone. When your levels are low, the question is not just how low, but where in that chain the failure is happening.

That one question changes everything about what you should do next.

Most testosterone panels stop at total testosterone, sometimes free testosterone. What they leave out are LH and FSH, and without those two numbers, you are essentially getting a snapshot of the output without knowing anything about whether the factory was even given the order to produce.

If your testosterone is low and your LH and FSH are also low or in the low-normal range, the problem is upstream. Your testicles are not being told to work. This is called secondary hypogonadism, which means the failure is in the signaling system rather than in the testicles themselves. The machinery is intact. The command is just not getting through.

This distinction matters because secondary hypogonadism is often reversible.

One option here is something called clomiphene citrate, which is a drug that blocks estrogen receptors in the hypothalamus and pituitary and tricks your brain into thinking estrogen is lower than it is, which causes it to ramp up LH and FSH production, which then drives the testicles to produce more testosterone through your body's own pathway. A 2025 systematic review and meta-analysis across 10 randomized controlled trials and 819 patients found a mean testosterone increase of 273.76 ng/dL with clomiphene or its close relative enclomiphene, which is a meaningful number when you consider that the difference between feeling normal and symptomatic is often in that range.

The distinction between clomiphene and enclomiphene is worth understanding. Clomiphene is a mix of two isomers, and one of them, the zuclomiphene isomer, has estrogenic activity that can cause side effects like mood changes and visual disturbances. Enclomiphene is the purified active isomer without that estrogenic activity. A 2024 study of 66 men found that the side effect rate with clomiphene was 47 percent compared to 13.8 percent with enclomiphene, while the median testosterone increase with enclomiphene was 166 ng/dL. Enclomiphene is not yet FDA-approved for this use, which affects access, but the mechanism is cleaner.

Another option for secondary hypogonadism is HCG, which stands for human chorionic gonadotropin, and it mimics LH directly at the level of the testicles rather than working through the brain. This is useful when the goal is to preserve testicular function and fertility, because it bypasses the broken signaling pathway and delivers the stimulus the testicles need.

Both of these approaches work by keeping your natural production system active rather than replacing it, which is why they preserve fertility in a way that TRT alone does not.

Now here is where the other scenario matters. If your testosterone is low and your LH and FSH are already elevated, the interpretation flips entirely. High LH and FSH alongside low testosterone means your brain is already sending the signal, loudly, and your testicles are not responding. This is called primary hypogonadism, which means the failure is at the level of the testicles themselves. The signaling chain is working. The factory is the problem.

In primary hypogonadism, trying to amplify the signal further with clomiphene or HCG alone is unlikely to produce meaningful results because the testicles do not have the capacity to respond. This is the situation where TRT is not just a shortcut, it is the appropriate intervention.

The fertility question on TRT is real but manageable. Exogenous testosterone suppresses LH and FSH, which means the testicles stop receiving the signal to produce sperm, which is the mechanism behind why TRT can impair fertility. The solution for men who want to preserve that function is to add HCG alongside TRT. A study by Coviello et al. found that 500 IU of HCG every other day was sufficient to maintain intratesticular testosterone at baseline levels in men whose gonadotropins were suppressed by exogenous testosterone, and intratesticular testosterone is what drives sperm production. That dose is what most protocols use for this purpose.

Before any of this matters, the foundations have to be in place. Sleep deprivation drives cortisol up and testosterone down through a well-established pathway involving the hypothalamic-pituitary axis. Visceral fat converts testosterone to estrogen through an enzyme called aromatase, and that elevated estrogen feeds back to suppress LH and FSH. Resistance training increases LH pulse frequency and Leydig cell sensitivity. These are not lifestyle suggestions layered on top of treatment, they are variables that directly affect whether any treatment works, because if the inputs driving suppression are still present, the signal will keep getting blunted regardless of what you add.

The reason this framework matters is that testosterone optimization without the right diagnosis is guesswork, and guesswork in this context has real consequences. Starting TRT when you have secondary hypogonadism means shutting down a system that was capable of working, suppressing LH and FSH, shrinking testicular volume over time, and committing to a protocol that is difficult to come off of, all for a problem that a signal-restoration approach might have solved. And staying off TRT when you have primary hypogonadism means expecting a system with structural failure to respond to behavioral optimization that it cannot act on.

The labs tell you which problem you actually have. Everything else follows from that.

---

References

1. Souza et al. 2025. "Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials." Archives of Endocrinology and Metabolism. 10 RCTs, 819 patients, mean increase 273.76 ng/dL. Source
2. Coviello AD et al. 2005. "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression." JCEM. 500 IU EOD maintained intratesticular testosterone at baseline. Source
3. Saffati et al. 2024. "Safety and efficacy of enclomiphene and clomiphene for hypogonadal men." Translational Andrology and Urology. 66 men, enclomiphene median increase 166 ng/dL, side effects 13.8% vs 47% with clomiphene. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness